From biosimilars to process intensification: 5 key trends in the biopharma space today

Efficiency in the biopharmaceutical space has never been more top-of-mind. The COVID-19 pandemic brought an unprecedented urgency to R&D and the key players delivered: Several groups produced a vaccine in record time. To maintain and improve on this level of efficiency, biopharma companies must reevaluate their infrastructure to make sure it’s optimized for long-term success. That means focusing on more than just speed – they need to produce more with less. In the gallery that follows, Priyanka Gupta, head of market entry strategy for protein based therapeutics, and Amélie Boulais, head of market entry strategy, virus based therapeutics, Sartorius, highlight five developments in this pursuit; two industry trends that are creating a need for greater efficiency and three ways companies are adapting to achieve it. © GettyImages/gorodenkoff